中国临床药理学杂志

艾司西酞普兰联合多巴丝肼治疗帕金森病患者的临床研究

PDF下载

郭莞莹 ^1a , 林熙汶 ^1b , 李辙 ^1b , 赵楠 ^1b , 舒可 ^1a

中国临床药理学杂志 | 临床与基础桥接研究 2025,41(3): 301-305

收起

中国临床药理学杂志 |临床与基础桥接研究 2025 , 41 (3) : 301 -305

艾司西酞普兰联合多巴丝肼治疗帕金森病患者的临床研究

全屏

郭莞莹^1a, 林熙汶^1b, 李辙^1b, 赵楠^1b, 舒可^1a

作者信息

^1a.昆明市第一人民医院，神经内科，云南昆明 650031

^1b.昆明市第一人民医院，神经外科，云南昆明 650031

通讯作者:

舒可，主任医师 MP: 15877990570 E-mail: keshu-9527@163.com

作者简介:

郭莞莹（1978-），女，副主任医师，主要从事脑血管病的临床诊疗工作

Clinical trial of escitalopram combined with levodopa and benserazide hydrochloride in the treatment of patients with Parkinson’s disease

Wan-ying GUO^1a, Xi-wen LIN^1b, Zhe LI^1b, Nan ZHAO^1b, Ke SHU^1a

Affiliations

^1a.Department of Neurology, The First People’s Hospital of Kunming, Kunming 650031, Yunnan Province, China

^1b.Department of Neurosurgery, The First People’s Hospital of Kunming, Kunming 650031, Yunnan Province, China

出版时间: 2025-02-17 doi: 10.13699/j.cnki.1001-6821.2025.03.001

文章导航

摘要

收起

目的

观察草酸艾司西酞普兰片联合多巴丝肼片治疗帕金森病患者的临床疗效及安全性。

方法

将帕金森病患者随机分为对照组和试验组。对照组给予多巴丝肼每次125 mg，tid，口服；试验组在对照组治疗的基础上，给予草酸艾司西酞普兰每次10 mg，qd，口服。2组患者均治疗3个月。比较2组患者的临床疗效、蒙特利尔认知评分量表（MoCA）、汉密尔顿抑郁量表（HAMD）和统一帕金森病评分量表（UPDRS）评分、白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、神经生长因子（NGF）水平，并进行安全性评价。

结果

试验组入组116例，脱落4例，最终有112例纳入统计分析；对照组入组116例，脱落2例，最终有114例纳入统计分析。治疗后，试验组和对照组的总有效率分别为82.14%（92例/112例）和65.79%（75例/114例），在统计学上差异有统计学意义（P<0.05）。治疗后，试验组和对照组的MoCA评分分别为（24.89±2.87）和（19.58±2.62）分，HAMD评分分别为（10.45±1.06）和（15.84±1.49）分，UPDRS评分分别为（40.06±5.28）和（47.78±5.52）分，IL-6水平分别为（4.12±0.63）和（6.71±1.13）mg·L^-1，TNF-α水平分别为（8.71±1.64）和（11.14±2.05）mg·L^-1，NGF水平分别为（41.56±5.20）和（30.47±4.14）ng·mL^-1，在统计学上差异均有统计学意义（均P<0.05）。试验组的药物不良反应主要有嗜睡和恶心呕吐，对照组的药物不良反应主要有恶心呕吐和便秘。试验组和对照组的总药物不良反应发生率分别为15.18%和12.28%，在统计学上差异无统计学意义（P>0.05）。

结论

草酸艾司西酞普兰片联合多巴丝肼片治疗帕金森病患者的临床疗效显著，其能够改善患者的炎症反应和神经营养因子水平，且不会增加药物不良反应的发生率。

关键词

草酸艾司西酞普兰片 / 多巴丝肼片 / 帕金森病 / 认知功能 / 神经营养因子 / 安全性评价

Abstract

收起

Objective

To observe the clinical efficacy and safety of escitalopram oxalate tablets combined with levodopa and benserazide hydrochloride tablets in the treatment of patients with Parkinson’s disease.

Methods

The patients with Parkinson’s disease were randomly divided into control group and treatment group. The control group received levodopa and benserazide hydrochloride tablets 125 mg per time, tid, orally. On the basis of control group, the treatment group received escitalopram oxalate tablets 10 mg per time, qd, orally. Two groups were treated for 3 months. The clinical efficacy, Montreal cognitive assessment (MoCA) scores, Hamilton depression rating scale (HAMD) scores, unified Parkinson’s disease rating scale (UPDRS) scores, the levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α) and nerve growth factor (NGF), and safety were compared between two groups.

Results

Treatment group was enrolled 116 cases, 4 cases dropped out, and 112 cases were finally included in the statistical analysis. Control group was enrolled 116 cases, 2 cases dropped out, and 114 cases were finally included in the statistical analysis. After treatment, the total effective rates of treatment and control group were 82.14% (92 cases / 112 cases) and 65.79% (75 cases / 114 cases), with significant difference (P<0.05). After treatment, the MoCA scores of treatment and control groups were (24.89±2.87) and (19.58±2.62) points, the HAMD scores were (10.45±1.06) and (15.84±1.49) points, the UPDRS scores were (40.06±5.28) and (47.78±5.52) points, the IL-6 levels were (4.12±0.63) and (6.71±1.13) mg·L^-1, the TNF-α levels were (8.71±1.64) and (11.14±2.05) mg·L^-1, the NGF levels were (41.56±5.20) and (30.47±4.14) ng·mL^-1, respectively. The differences of above indexes were statistically significant between two groups (all P<0.05). The adverse drug reactions of treatment group were somnolence and nausea/vomiting, while those in control group were nausea/vomiting and constipation. The total incidences of adverse drug reactions in treatment and control groups were 15.18% and 12.28%, without statistically significant difference (P>0.05).

Conclusion

Escitalopram oxalate tablets combined with levodopa and benserazide hydrochloride tablets significantly improves clinical efficacy in the treatment of patients with Parkinson’s disease, which can significantly ameliorate the inflammatory responses and neurotrophic factor levels, without increasing the incidence of adverse drug reactions.

Key words

escitalopram oxalate tablet / levodopa and benserazide hydrochloride tablet / Parkinson’s disease / cognitive function / neurotrophic factor / safety evaluation

引用本文

郭莞莹, 林熙汶, 李辙, 赵楠, 舒可. 艾司西酞普兰联合多巴丝肼治疗帕金森病患者的临床研究. 中国临床药理学杂志, 2025 , 41 (3) : 301 -305 . DOI: 10.13699/j.cnki.1001-6821.2025.03.001

Wan-ying GUO, Xi-wen LIN, Zhe LI, Nan ZHAO, Ke SHU. Clinical trial of escitalopram combined with levodopa and benserazide hydrochloride in the treatment of patients with Parkinson’s disease[J]. Chinese Journal of Clinical Pharmacology, 2025 , 41 (3) : 301 -305 . DOI: 10.13699/j.cnki.1001-6821.2025.03.001

基金

收起

云南省科技厅科技计划基金资助项目(202301AY070001-286)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

2025年第41卷第3期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.13699/j.cnki.1001-6821.2025.03.001

接收时间：2024-08-08
首发时间：2026-08-04
出版时间：2025-02-17

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2024-08-08

基金

云南省科技厅科技计划基金资助项目(202301AY070001-286)

作者信息

^1a.昆明市第一人民医院，神经内科，云南昆明 650031

^1b.昆明市第一人民医院，神经外科，云南昆明 650031

通讯作者:

舒可，主任医师 MP: 15877990570 E-mail: keshu-9527@163.com

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zglcylxzz/CN/10.13699/j.cnki.1001-6821.2025.03.001

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT